Scaling Up Efforts to Penetrate the Central and South American Market with Brazil as a Strategic Base

SK Biopharm announced on the 29th that, in conjunction with participating in the presidential economic delegation, it signed a strategic work agreement (MOU) for cenobamate with Eurofarma, a leading local pharmaceutical company, in São Paulo, Brazil. With the launch of cenobamate in Brazil as the starting point, the company will fully scale up its efforts to penetrate the Central and South American market with a population of 600 million.


During this visit to Brazil, Lee Donghun, President of SK Biopharm, joined the economic delegation, where he directly reviewed the status of cenobamate’s launch in Brazil and local partnerships, as well as coordinated plans for further research and development and expansion of business cooperation in the future. Together with Eurofarma, SK Biopharm plans to actively leverage regional infrastructure and commercial capabilities to build a healthcare ecosystem spanning across Central and South America.

On the 28th (local time) at the "Korea-Brazil Business Roundtable" held in São Paulo, Brazil, Ryu Jin, Chairman of the Korea Economic Association (from the left in the photo), Kim Jungkwan, Minister of Trade, Industry and Energy, Lee Donghun, President of SK Biopharm, Marco Billi, Global CEO of Eurofarma, Marcio Elias Rosa, Minister of Development, Industry, Trade and Services of Brazil, and Laudemir Müller, Chairman of Apex Brazil, took a commemorative photo.

On the 28th (local time) at the "Korea-Brazil Business Roundtable" held in São Paulo, Brazil, Ryu Jin, Chairman of the Korea Economic Association (from the left in the photo), Kim Jungkwan, Minister of Trade, Industry and Energy, Lee Donghun, President of SK Biopharm, Marco Billi, Global CEO of Eurofarma, Marcio Elias Rosa, Minister of Development, Industry, Trade and Services of Brazil, and Laudemir Müller, Chairman of Apex Brazil, took a commemorative photo.

View original image

This MOU, achieved as a major outcome of the president’s visit to Brazil and the activities of the economic delegation, will further advance the strategic partnership between the two companies by focusing on five key initiatives for expanding in the Central and South American market through the launch of cenobamate in Brazil: 1) maximizing the product value of cenobamate; 2) collaborating on central nervous system (CNS) pipeline; 3) joint research and development (R&D) on rare epilepsies; 4) expanding the entry of cenobamate into the Central and South American market; 5) expanding the digital healthcare business through the existing joint venture 'Mentis Care'.


The two companies will accelerate their approach to the epilepsy treatment market centered on cenobamate. In addition to continuing research and business cooperation to broaden indications and enhance the therapeutic value of cenobamate, they plan to gradually expand the number of launch countries by capitalizing on Eurofarma’s robust local regulatory, distribution, and commercialization network. Through these efforts, their strategy is to establish cenobamate as a leading epilepsy treatment in Central and South America.


Meanwhile, cenobamate (locally branded as 'XCOPRI®') will officially launch in the Brazilian market through Eurofarma in August. Having already introduced the product in Peru and Chile, entering Brazil—the largest pharmaceutical market in Central and South America—is expected to be a turning point for cenobamate’s regional diffusion and business expansion.


The two companies will also accelerate the expansion of the digital healthcare business centered on their existing joint venture, Mentis Care. They plan to further develop digital medical solutions integrated with mobile applications to support patient seizure management and real-time health monitoring, and to build a digital healthcare platform that enables medical professionals to more precisely assess patient conditions.



Lee Donghun, President of SK Biopharm, stated, "This presidential visit to Brazil has given us the meaningful opportunity to further strengthen our comprehensive partnership with Eurofarma, not only in expanding cenobamate’s market but also in the CNS pipeline, rare epilepsy R&D, and digital healthcare. Above all, I am deeply gratified that we can deliver the innovative value of cenobamate to patients and healthcare professionals in Central and South America. I would also like to thank our partner Eurofarma for their close collaboration."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing